1064-P: Use of Temporary Target during the MiniMed™ 670G System Pivotal Trials.

Background: The MiniMed™ 670G system targets glucose levels to 120mg/dL (6.7mmol/L) and has a temporary target (TT) of 150mg/dL (8.3mmol/L) that can be set from 2-12 hours. An exploratory analysis of glycemic outcomes and TT use during the 3-month MiniMed™ 670G system pivotal trials was conducted. Methods: Data from 151 children (n=46, 2-6 years and n=105, 7-13 years) and 124 adolescents and adults (n=30, 14-21 years and n=94, 22-75 years) during 2-week Manual Mode use (run-in), followed by 3-month Auto Mode use (study), were analyzed by percentage of TT use. Results: The median (IQR) of TT use for those 2-6 years was 4.1% (0.6-16.3%); for 7-13 years was 0.4% (0-2.1%) and ≥14 years was 0.4% (0-1.2%). Glycemic outcomes for the 2-6 years are shown by percentage of TT use (<4% or ≥4%). A trend in baseline data show that the ≥4% group had less hypoglycemia (3.0% vs. 4.3%) and more hyperglycemia (44.9% vs. 36.8%), suggesting preemptive hypoglycemia avoidance. Conclusions: Improved glycemia was observed in the 2-6 years group regardless of TT use during study phase, compared to baseline run-in. The higher glucose target was used more often in the youngest cohort, suggesting the TT feature is important for young children with T1D using automated insulin delivery. Disclosure: J. Shin: Employee; Self; Medtronic. X. Chen: None. T.L. Cordero: Employee; Self; Medtronic. S.W. Lee: Employee; Self; Medtronic. F.R. Kaufman: Employee; Self; Medtronic. [ABSTRACT FROM AUTHOR]